Introduction: Erb-b2 receptor tyrosine kinase 2 gene (ERBB2) (also called HER2) has long been recognized as an oncogenic driver in some breast and gastroesophageal cancers in which amplification of this gene confers sensitivity to treatment with Erb-b2 receptor tyrosine kinase 2 (ERBB2)-directed agents. More recently, somatic mutations in ERBB2 have been reported in 1% to 2% of patients with lung adenocarcinoma. Previous case series have suggested clinical tumor responses using anti-ERBB2 small molecules and antibody therapies.
Introduction
Treatment of patients with metastatic NSCLC has historically relied on choosing the most efficacious chemotherapy regimen on the basis of histologic subtypes. With the discovery of driver mutations, such as EGFR mutations and the development of targeted tyrosine kinase inhibitor (TKI) therapies against these specific mutations, the treatment paradigm has shifted. There are now U.S. Food and Drug Administration-approved targeted therapies for lung cancers with mutations in EGFR (also known as erb-b2 receptor tyrosine kinase 1 [ERBB1/HER1]), and gene rearrangements in anaplastic lymphoma receptor tyrosine kinase gene (ALK), and ROS-1. Several other recurrent genomic alterations have been identified and can also be targeted with off-label use of targeted therapies. NSCLC with erb-b2 receptor tyrosine kinase (ERBB2/HER2) mutations appears to be one such example.
Earlier studies on ERBB2 aberrations in lung cancers focused on ERBB2 protein overexpression analyzed by immunohistochemistry (IHC) and gene amplification as detected by fluorescence in situ hybridization. A decade ago, trials of targeted therapies in ERBB2-amplified NSCLC yielded disappointing results. In a study including patients with tumors that had ERBB2 overexpression determined by IHC, treatment with trastuzumab plus cisplatin and gemcitabine was well tolerated, but there was no clear relationship between the intensity of ERBB2 overexpression and the likelihood of response. 1 A randomized phase II trial of cisplatin-gemcitabine with or without trastuzumab for ERBB2-positive NSCLC (overexpression defined by IHC 2þ/3þ, amplification by fluorescence in situ hybridization, or elevated circulating serum ERBB2 extracellular domain by enzyme-linked immunosorbent assay) also showed no clinical benefit.
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ERBB2 kinase domain mutations were first reported in 2004 to be present in approximately 4% of unselected lung tumors and in 10% of the adenocarcinoma subtype of lung cancer. 3 Subsequently, Shigematsu et al. reported ERBB2 mutations in only 1.5% of NSCLC cases, but with higher prevalence in women and nonsmokers. 4 There is less genetic diversity of ERBB2 mutations than of EGFR mutations, as 96% are exon 20 insertions and 83% of those are a recurrent 12-base pair insertion causing duplication of amino acids YVMA at codon 775. 5 In 2006, Cappuzzo et al. reported a case of a patient with an ERBB2 exon 20 mutation (G776L) and an EGFR exon 21 mutation (A859T) that responded to weekly trastuzumab and paclitaxel. 6 Subsequently, De Grève et al. reported on three patients with ERBB2 exon 20 mutation responding to afatinib. 7 In 2013, Mazières et al. 8 identified 65 of 3800 patients (1.7%) whom testing showed to have ERBB2-mutant NSCLC, and of those 65 patients, 16 received ERBB2-targeted treatments after conventional chemotherapy. The authors confirmed the higher prevalence of ERBB2 mutations among women and never-smokers. In addition, they observed a disease control rate (DCR) of 93% for trastuzumab-based therapies and a DCR of 100% for afatinib but no response to other targeted drugs such as lapatinib and masatinib (a TKI with activity against c-Kit, platelet-derived growth factor receptor, and fibroblast growth factor receptor 3). In larger recently published series, Mazières et al. 9 identified 101 patients from 38 centers. They again noted predominance in females (62.4%) and nonsmokers (60.4%). Sixty-five patients received ERBB2-targeted therapies, and the overall response rate (RR) was 50.9%. The RR, DCR, and progression-free survival (PFS) were 50%, 75%, and 5.1 months, respectively, for trastuzumab in combination with chemotherapy. For afatinib, the RR, DCR, and PFS were 18.2%, 63.7%, and 3.9 months, respectively.
In the current study, we identified a total of nine patients between two institutions with tumors harboring the ERBB2 exon 20 insertion mutation who received ERBB2-targeted therapies and report their outcomes. As there are currently limited data available on ERBB2-based mechanisms of acquired resistance to targeted therapies, we also postulated potential resistance mechanisms after progression during targeted therapies. We identified a de novo phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation and ERBB2 copy number gain as potential mechanisms for resistance.
Methods

Patient Selection
Our cohort included patients with advanced NSCLC with molecular testing demonstrating ERBB2 mutations at Stanford University in Stanford, California(patients 1-7) between April 2013 and May 2016 and at Sun Yat-sen University Cancer Center (Guangzhou, People's Republic of China) from August 2014 to October 2015 (patients 8 and 9) who were treated with ERBB2-targeted therapies. The cohort was generated with assistance from the Stanford Cancer Institute Research Database group under an institutional review board-approved retrospective review protocol. The institutional review board of the Stanford University School of Medicine approved of this study. This research was also approved by the Sun Yat-sen University Cancer Center Research Ethics Board.
Targeted Therapy
Docetaxel was dosed at 35 mg/m 2 on days 1 and 8 of a 21-day cycle initially for patient 2 and then reduced to 25 mg/m 2 . Paclitaxel was dosed at 60 mg/m 2 weekly. Vinorelbine was dosed at 25 mg/m 2 weekly with trastuzumab, 2 mg/kg weekly (after a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks. Afatinib was dosed at 40 mg/d. Ado-trastuzumab emtansine was dosed at 3.6 mg/kg intravenously every 3 weeks.
Molecular Testing in Tissue and Plasma
We performed several different methods of molecular testing on biopsy samples. ERBB2 mutations in tissue samples were identified by using a Stanford polymerase chain reaction-based ERBB2 sizing assay or the nextgeneration sequencing (NGS)-based methods Stanford Solid Tumor Actionable Mutation Panel assay, 10 NGSbased Foundation One assay, 11 or Geneseeq assay (Geneseeq Technology [Toronto, Ontario, Canada]). DNA (ctDNA) was analyzed by using NGS-based cancer personalized profiling by deep sequencing (CAPP-Seq) with noninvasive copy number calling for EGFR and ERBB2 as previously described. [13] [14] [15] Response Assessment
Response to therapy was measured by using Response Evaluation Criteria in Solid Tumors, version 1.1. RR was defined as the percentage of patients whose cancer showed partial response (there was no complete response) per Response Evaluation Criteria in Solid Tumors, version 1.1 criteria. PFS was defined as the length of time during and after the treatment with ERBB2-targeted therapy for which patient lived with the disease and without it getting worse.
Results
Case Reports of Responders
Patient 1. The first patient was a 64-year-old white woman with a minimal smoking history in whom stage IIIA lung adenocarcinoma was diagnosed in early 2011. She underwent neoadjuvant cisplatin and pemetrexed treatment for 2 months, followed by surgical resection. The pathologic examination results were consistent with T1N2 poorly differentiated adenocarcinoma of lung primary.
Recurrent metastatic disease then developed mainly in the patient's liver after she had completed definitive chemoradiotherapy. She was treated with carboplatin, gemcitabine, and bevacizumab followed by gemcitabine and bevacizumab maintenance as part of a clinical trial and was able to achieve stable disease for 6 months before progression. She was next treated with docetaxel for 1 month with rapid progression, followed by pemetrexed alone for 2.5 months with slight progression, and then with irinotecan for 2 months, with significant progression and near replacement of liver with tumor. At that time she was found to have ERBB2 exon 20 insertion mutation (A775_G776 insSVMA) by NGS testing and she began receiving vinorelbine and trastuzumab. She tolerated the treatment well. She achieved radiographically stable disease for 6 months and significant clinical improvement before progression of disease in all sites, with a subsequent decision to pursue hospice.
Patient 2. The second patient was a 67-year-old Asian female never-smoker in whom T3N1M1a stage IV lung adenocarcinoma with biopsy-proven bilateral lung involvement was diagnosed. Mutational studies revealed in-frame insertion in exon 20 of the ERBB2 gene (A775_G776 insYVMA).
She received carboplatin and pemetrexed chemotherapy for 3 months, followed by 6 months of pemetrexed maintenance. Progressive disease then developed and she began receiving trastuzumab and docetaxel, with a partial response as her best response. She progressed after 8 months, at which point her therapy was changed to afatinib. The patient took afatinib for 1 month and her computed tomography (CT) scan showed response, but she had to change therapy because of insurance denial and was changed back to trastuzumabbased therapy.
Patient 3. The third patient was a 61-year-old white woman with a 10-pack-year smoking history. Stage IV lung carcinoma was diagnosed when she presented with extensive bone disease, including a lytic lesion in the right femur and a mass in the left lower lung. She underwent urgent stabilization of the right femur. The results of pathologic examination of samples from the operation were consistent with metastatic carcinoma of lung primary. She was found to have an ERBB2 exon 20 insertion mutation (A775_G776 insYVMA).
She was treated with carboplatin, paclitaxel, bevacizumab, and an investigational anti-mesenchymalepithelial transition therapy with initial mild decrease in lung mass and nodules after 1 month and then mild progression for 14 months. She was subsequently treated with vinorelbine and trastuzumab for 7 months and then docetaxel and trastuzumab with focal palliative radiation to control lesion bone metastases. She achieved stable disease as her best response for 5 additional months. At progression she was treated with singleagent pemetrexed, after which she progressed and transitioned to hospice care.
Patient 4.
The fourth patient was a 36-year-old female Asian nonsmoker in whom stage IV lung adenocarcinoma was diagnosed when she presented with a large left-sided pleural effusion and lung masses. CT-guided fine-needle aspiration showed adenocarcinoma consistent with lung primary. She was found to have an ERBB2 exon 20 insertion mutation (exact sequence unknown).
She was treated with carboplatin, pemetrexed, and bevacizumab that were first followed by pemetrexed and bevacizumab maintenance, with initial mild improvement and then progression after 4.5 months. She was then treated with erlotinib in the control arm of a clinical trial with rapid progression within 1 month. She started receiving afatinib, 40 mg daily, on the basis of the ERBB2 mutation and had improved disease after 2 months, with a best response of 21% reduction and then progression after 3 more months (a total of 5 months of clinical benefit). She then began receiving vinorelbine and trastuzumab and had a partial response to therapy after 4 months. Her disease progressed after 6 months of therapy, and she was switched to docetaxel plus trastuzumab. She achieved stable disease after 1 month and then progressed systemically in the lungs, with adrenal metastasis after 3 months. She then started receiving ado-trastuzumab emtansine, but repeat imaging showed progressive disease after 2 months. She required three separate rounds of stereotactic radiation for brain lesions during the aforementioned treatments. She then received nivolumab for 1 month and continued to have progression. She next enrolled in a clinical trial with a central nervous system (CNS)-active chemotherapy for 2 months but continued to show progression with multiple new brain metastases and progression in her chest. The patient received whole brain radiation at that point. She was then rechallenged with afatinib daily in combination with bevacizumab intravenously every 3 weeks and tolerated the therapy well, with mixed response at 6 weeks but eventual progression in the liver after 3 months.
The demographic characteristics, treatments, and responses for the aforementioned four patients are summarized in Table 1 . Representative CT imaging of the best responses is shown in Figure 1 . A swimmer plot summarizing the treatment courses of the four patients treated with ERBB2-targeted therapy is shown in Figure 2 .
Potential Resistance Mechanisms
To further understand potential resistance mechanisms upon progression during targeted therapies, we performed NGS-based genotyping on postprogression tumor biopsy samples and/or CAPP-Seq on postprogression plasma specimens available from these patients.
Patient 2 had a repeat biopsy of a left lung nodule after progression during trastuzumab/docetaxel therapy and 1 month of afatinib treatment. In addition to ERBB2 exon 20 insertion mutation, she was also found to have several variants of unknown significance, including retinoblastoma 1 gene (RB1) R320L, astrotactin 1 gene (ASTN1) R214W, lamin tail domain containing 1 gene (IFLTD1) L71P, DEAD-box helicase 1 gene (DDX1) V429I, and BMP/retinoic acid inducible neural specific 3 gene (FAM5C) D431V, in her repeat biopsy sample by NGS. However, because these variants were not included in the genotyping assay preformed on the pretreatment biopsy sample, whether these were preexisting or acquired mutations is unclear.
For patient 3, the initial femur biopsy sample leading to the diagnosis of lung carcinoma was retested by NGS. In addition to the previously identified ERBB2 mutation, we also detected PIK3CA R88Q mutation in the femur biopsy sample. In the plasma sample obtained upon progression during trastuzumab treatment plus chemotherapy, we observed a de novo mutation that was not present in the tumor biopsy: PIK3CA R425L. The allele frequency of this mutation was 0.42%. We did not observe the ERBB2 exon 20 insertion, which was most likely due to the low ctDNA concentration. According to a binomial model, the expected probability of detecting the mutation is only 58%, given the median sequencing depth at the position (2047) and a ctDNA concentration of 0.42%. The PIK3CA R88Q mutation observed in the tumor was not reassessed with the ctDNA NGS panel. These mutations may thus represent putative resistance mechanisms.
For patient 4, plasma samples were obtained upon progression during her initial chemotherapy regimen (carboplatin, pemetrexed, and bevacizumab), upon progression during erlotinib therapy, and upon progression during afatinib therapy. These were tested by using CAPP-Seq. The ERBB2 exon20 insertion was identified in all plasma samples with increasing allele fraction over time. Furthermore, ERBB2 copy number gain was present in all samples, and the copy number level normalized to ctDNA content increased over time. There was a dramatic increase in ERBB2 copy number at the time of progression during afatinib therapy, suggesting that this represents a potential resistance mechanism (Fig. 3) .
Summary of Nonresponders
We treated five patients (patients 5-9) who did not respond to ERBB2-targeted therapies with afatinib-and/ or trastuzumab-based therapies. Their clinical, pathologic, and treatment characteristics are summarized in Table 2 .
Discussion
Consistent with prior reports, our experience with patients with ERBB2-mutated NSCLC demonstrates that ERBB2 is a targetable driver mutation. In addition, we explored the potential resistance mechanisms to ERBB2-targeted therapies. Our patients with ERBB2 mutations tend to be younger with little or no smoking history. Four of the nine patients treated with ERBB2-targeted therapies had a response (RR 44%). A total of six patients received afatinib, and of those patients, two had a response (RR 33%). A total of six patients received trastuzumab in combination with chemotherapy, and four of them had a response (RR 67%). From our experience, ERBB2-targeted therapy can provide disease control for patients with metastatic ERBB2-mutated NSCLC that has progressed during previous therapies. The PFS times during each therapy ranged from 3 to 10 months. Our results are consistent with those reported by Mazières et al. 8, 9 and Costa et al. 16 To the best of our best knowledge, this is the first study describing putative resistance mechanisms to ERBB2-targeted therapies in patients with lung cancer. Note: ERBB2/HER2-targeted therapies in bold. Best response as determined by Response Evaluation Criteria in Solid Tumors, version 1. ERBB2/HER2, erb-b2 receptor tyrosine kinase 2 gene; PFS, progression-free survival; W, white; F, female; A, Asian; Adeno, adenocarcinoma; NGS, next-generation sequencing; Carbo, carboplatin; Gem, gemcitabine; Bev, bevacizumab; Pem, pemetrexed; Tras, trastuzumab; PD, progressive disease; PR, partial response; STAMP, Stanford Solid Tumor Actionable Mutation Panel; RB1, retinoblastoma 1 gene; ASTN1, astrotactin 1 gene; IFLTD1, lamin tail domain containing 1 gene; DDX1, DEAD-box helicase 1 gene; FAM5C, BMP/retinoic acid inducible neural specific 3 gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; Met, mesenchymal-epithelial transition; PCR, polymerase chain reaction; ERBB2/HER2, erb-b2 receptor tyrosine kinase 2; n/a, not available.
Previously, one preclinical study showed that the G776 YVMA insertion in ERBB2 is expected to induce allosteric effects that may influence inhibitor binding. 17 In this study, we identified potential resistance mechanisms by using CAPP-Seq ctDNA analysis on plasma samples collected at the time of progression. In patient 3 we identified a novel mutation-PIK3CA R425L-that may be a resistance mechanism after treatment with trastuzumab. Interestingly, acquired PIK3CA mutations have been rarely reported as a mechanism of resistance to EGFR TKI therapy in EGFR-mutated NSCLC. 18, 19 For patient 4, target amplification by increasing ERBB2 copy number is a plausible resistance mechanism to afatinib. Resistance to ERBB2-targeted therapies has also been observed in other ERBB2-driven cancers. In the case of breast cancer, putative resistance mechanisms include PIK3CA mutation, Src activation, insulin-like growth factor-I receptor signaling, and c-Met overexpression. 20 Activation of the PI3K pathway has also been found to contribute to trastuzumab resistance in breast cancer. 21, 22 In gastric cancer, a recent preclinical study showed that in gastric cancer cells, MACC1, MET transcriptional regulator gene (MACC1) promoted the Warburg effect mainly through the PI3K/AKT signaling pathway, which enhanced trastuzumab resistance. 23 Understanding resistance mechanisms, through repeat tumor biopsies and analysis of ctDNA, is critical to the design of more potent therapies that overcome recurrent escape mechanisms.
There are issues that need to be considered when administering ERBB2-targeted therapies. Tolerability of these medications can be a challenge for patients. In our experience, trastuzumab (at 2 mg/kg, consistent with a previous report 6 ) plus chemotherapy was generally well tolerated. On the other hand, afatinib toxicities can be challenging for some patients, as diarrhea and mucositis can be dose limiting. Afatinib was dosed at 50 mg/d in the series by De Grève et al., 7 and we chose to dose afatinib at a slightly lower dose of 40 mg/d. Recently, a pulse dosing of afatinib at a 280-mg weekly dose was reported to have promising results and apparent tolerability-with less severe diarrhea than might have been anticipated-and this dosing regimen is worth further investigation. 16 Additionally, brain metastases often develop in patients with ERBB2-mutated NSCLC, and trastuzumab is not known to cross the blood-brain barrier and therefore likely would not affect CNS metastases. Therefore, monitoring and treatment of CNS metastases may need to be considered separately.
Potential therapeutic roles for other ERBB2-targeted agents are worthy of further investigation. Lapatinib is another ERBB2-targeted TKI, but patients treated with lapatinib did not respond in two separate series by Mazières et al. 8, 9 Dacomitinib has shown activity in ERBB2-mutated NSCLC, 24 as has neratinib, 25 with more trials of this agent still ongoing alone and in combination with other agents (NCT01827267, NCT01953926, and NCT02593708). Another ERBB2 TKI, AP32788, has shown promise in preclinical studies involving ERBB2 exon 20 insertion-mutant cancer cell lines, 26 and a clinical trial is ongoing (NCT02716116). Potential activity of ado-trastuzumab emtansine is also intriguing; although our treated patient did not respond to the medication, there has been one case report showing response to the medication in a patient with ERBB2 exon 20 insertion mutation, overexpression, and amplification. 27 Another Fc-modified chimeric monoclonal antibody against ERBB2, margetuximab (MGAH22), is being tested in trials (NCT01148849). Because we identified PIK3CA mutation as a potential resistance mechanism to ERBB2-targeted therapy, there is a rationale for combined treatment. However, to the best of our knowledge 
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Targeting ERBB2-Mutated Metastatic NSCLC there are currently no trials combining a PIK3CA inhibitor with an ERBB2 inhibitor in NSCLC.
Immunotherapies are also worth considering in the treatment of ERBB2-mutated disease. Although our patient did not respond to nivolumab, there is a case report showing response to this medication. 28 The programmed death ligand 1 expression status of our patients' tumors was unknown, and most patients were not treated with these agents because their treatment course preceded the U.S. Food and Drug Administration's approval of checkpoint inhibitors, but it would have been interesting to observe the RRs to these agents in patients with ERBB2-mutant NSCLC.
One unanswered question is which tumor genotypes are predictive of response. All four patients who responded to targeted therapy had tumors with exon 20 insertion mutations, but patients 5 and 6, who also had the most common exon 20 insertion mutations, did not respond to targeted therapies. Patients 7, 8 , and 9 had tumors with uncommon ERBB2 mutations and did not respond to therapy, but we included them in this report to inform other clinicians. There is limited literature on the response to ERBB2-targeted therapies from different mutations. We note that in the series by Mazières et al., 8 all ERBB2 mutations identified were in-frame insertions of exon 20, with duplication of amino acids YVMA at codon 775. Given the small number of patients in our series, it is not possible to conclude whether a certain mutation predicts response to therapy. In addition, there may be other unidentified driver mutations for the nonresponders, and there may be host factors that affect responses to these therapies.
We note several limitations in our study. The sample size in this study is small, and therefore, no conclusive statistical associations can be made regarding the effectiveness of targeted therapies or any factors that can predict response to targeted therapies. In addition, our study focused on examining potential resistance mechanisms upon progression during ERBB2-targeted therapies; we did not examine any potential primary resistance mechanisms in the nonresponders. Lastly, we had experiences with afatinib and trastuzumab (in combination with chemotherapy), and only one patient received ado-trastuzumab; our patients did not receive other available or experimental ERBB2-targeted therapies.
Overall, we recommend testing for ERBB2 mutations in addition to other uncommon driver genomic alterations, for patients whose NSCLC tumors are negative for genomic alterations in EGFR, ALK, and ROS1. Small molecule ERBB2 inhibitors or ERBB2 monoclonal antibodies may provide an additional therapy in these patients, but in our series and in previously published data, the RR and duration when they are administered have been modest compared with those when TKIs against other molecular drivers are used. It is hoped that with ongoing research, additional highly effective and tolerable ERBB2 therapies will be identified to expand treatment options for ERBB2-mutant NSCLC.
